Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPIV200 + sargramostim
- Development stage
- Unknown
- Lead developer
- Marker Therapeutics
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
**TPIV200 + sargramostim** is a combination immunotherapeutic regimen comprising a multi-epitope folate receptor alpha (FRα) peptide vaccine (TPIV200) and sargramostim, a recombinant human granulocyte macrophage colony-stimulating factor (GM-CSF). TPIV200 is designed to stimulate CD4+ and CD8+ T-cell responses against folate receptor alpha, which is frequently overexpressed in ovarian cancer and triple-negative breast cancer (TNBC). Sargramostim acts as an immune adjuvant, enhancing antigen presentation and T-cell priming by promoting the activation of dendritic cells and macrophages. The combination is under clinical evaluation for the prevention of recurrence in TNBC and for treatment of ovarian cancer in regimens intended to elicit durable, tumor-specific immune responses.
- Other names
- TPIV200 + GM-CSFTPIV200 + Leukine
02
Targets
FOLR1 (FRα)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on TPIV200 + sargramostim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TPIV200 + sargramostim.